Clinical perspective, offered as context rather than as advice.
Body composition tracking via bioimpedance on lean mass (InBody scan every 3 months):
| Metric | Baseline | Month 3 | Month 6 | Month 9 |
|---|---|---|---|---|
| Skeletal Muscle (lbs) | 77 | 67 | 68 | 75 |
| Body Fat (lbs) | 109 | 79 | 57 | 41 |
| Body Fat % | 43% | 35% | 26% | 22% |
| Visceral Fat (cm²) | 174 | 119 | 94 | 64 |
Note: skeletal muscle mass dipped initially then recovered with consistent resistance training + high protein. The visceral fat reduction is where the metabolic magic happens.
Dr.ReproEndo said:Body composition tracking via bioimpedance on lean mass (InBody scan every 3 months): Metric Baseline Month 3 Month 6 Month 9 Skeletal Muscle (lbs) 77…
All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.
Happy to go further on any of that.
Dr.ReproEndo said:Body composition tracking via bioimpedance on lean mass (InBody scan every 3 months): Metric Baseline Month 3 Month 6 Month 9 Skeletal Muscle (lbs) 77…
Adding the part of the answer the thread has not reached. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne concrete data point for the thread. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.
One thing that is still open after Dr.ReproEndo’s answer:
What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?